In addition, the possible off-target effects by STK32C depletion can be expected such as p53/MDM2 in CRCs, since we acknowledge the limitation of using only two CRC cell lines, HCT116 (p53 wild-type) and SW620 (p53 mutant), and recognize the necessity of validating our findings across a broader panel of CRC models including patient-derived samples or clinical datasets. The gene discussed is STK32C; the disease is colorectal carcinoma.